| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.6 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |